New drug shows promise for rare joint tumor
NCT ID NCT04488822
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 3 trial tests the drug pexidartinib in 40 adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in joints that causes pain and limits movement. The study focuses on people whose tumors are severe and cannot be helped by surgery. Researchers are measuring how many participants see their tumors shrink after 25 weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pexidartinib (TURALIO)
What this could lead to
If successful, pexidartinib could offer a non-surgical treatment option for people with symptomatic TGCT that is difficult to operate on.
What could go wrong
This is a small, single-arm study with no placebo group, so results may be less reliable. Pexidartinib also has known risks, including liver toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Ji Shui Tan Hospital
Beijing, China
-
Fudan University Shanghai Cancer Center
Shanghai, China
-
National Taiwan University Hospital
Taipei, Taiwan
-
Peking University Cancer Hospital
Beijing, China
-
Shanghai General Hospital
Shanghai, China
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
-
Zhejiang Cancer Hospital
Hangzhou, China